Sign In
Buy LLY
$1,192.80
+22.94 (+1.96%)
At Close: Aug 06, 2026
Lilly's blood cancer drug meets main goal in late-stage study
06:57am, Monday, 08'th Sep 2025
Eli Lilly said on Monday its blood cancer treatment Jaypirca met the main goal in a late-stage study in patients who have not received prior treatment.
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine
Top 50 High-Quality Dividend Stocks For September 2025
12:18pm, Saturday, 06'th Sep 2025
I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto
Novo Nordisk Vs Eli Lilly: Novo A Clear Winner
01:10pm, Friday, 05'th Sep 2025
Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment t
Eli Lilly And Company (LLY) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
12:11pm, Friday, 05'th Sep 2025
Eli Lilly and Company (NYSE:LLY ) 2025 Wells Fargo Healthcare Conference September 5, 2025 9:30 AM EDT Company Participants Patrik Jonsson - Executive VP & President of Lilly International Mike Czapar
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day?
09:00am, Friday, 05'th Sep 2025
Eli Lilly (LLY 0.56%) is typically a market outperformer, but it has had a challenging year so far. Besides general market volatility, the company has dealt with clinical setbacks, lower-than-expected
2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts
04:29am, Friday, 05'th Sep 2025
While many dividend stocks are viewed as slow-growing investments, this isn't always the case. Right now, investment bank analysts up and down Wall Street are bullish for a pair of dividend-paying sto
Lila Biologics Announces Collaboration with Lilly For Radioligand Therapy Discovery and Development
09:00am, Thursday, 04'th Sep 2025
Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Diseases Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Disease
The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be present
Where Will Eli Lilly Be in 3 Years?
04:25am, Thursday, 04'th Sep 2025
Eli Lilly (LLY 0.15%) stock has soared in the triple digits over the past three years thanks to one particular product line: its weight-loss drugs. Lilly is the maker of tirzepatide, sold under the na
Eli Lilly's Stock Fall Is An Opportunity
12:09am, Thursday, 04'th Sep 2025
I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes,
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Insider Watch: 3 CEOs Buying the Dip
12:31pm, Wednesday, 03'rd Sep 2025
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture.
Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
09:30am, Wednesday, 03'rd Sep 2025
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLY
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
05:32pm, Tuesday, 02'nd Sep 2025
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
